Fusion Pharmaceuticals Inc. Noninterest Expense Offering Cost
Fusion Pharmaceuticals Inc. reported Noninterest Expense Offering Cost of $19.45 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:NoninterestExpenseOfferingCost · last filed 2022-03-17
- Fusion Pharmaceuticals Inc. noninterest expense offering cost for the quarter ending 2020-12-31 was $14.85M.
- Fusion Pharmaceuticals Inc. noninterest expense offering cost for the quarter ending 2020-09-30 was $0.00.
- Fusion Pharmaceuticals Inc. noninterest expense offering cost for the quarter ending 2020-06-30 was $19.45M.
- Fusion Pharmaceuticals Inc. noninterest expense offering cost for fiscal 2020 was $19.45M.
| Period end | Noninterest Expense Offering Cost 3 month | Noninterest Expense Offering Cost 6 month | Noninterest Expense Offering Cost 9 month | Noninterest Expense Offering Cost 12 month |
|---|---|---|---|---|
| 2020-12-31 | $14.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $14.85M derived: sum of 2 quarters · filed 2022-03-17 | $34.29M derived: sum of 3 quarters · filed 2022-03-17 | $19.45M 10-K · filed 2022-03-17 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $19.45M derived: sum of 2 quarters · filed 2021-11-09 | $4.60M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $19.45M 10-Q · filed 2021-11-09 | $4.60M 10-Q · filed 2020-08-11 |